A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new ...

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS ...

Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...

Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic ...

CAYMAN ISLANDS - Silexion Therapeutics Corp. (NASDAQ: SLXN), a biotech firm focusing on RNA interference (RNAi) treatments, ...

Silexion Therapeutics (SLXN) announced new preclinical data for SIL-204, its next-generation siRNA therapeutic candidate. The findings ...

New preclinical findings provide validation for Silexion’s new systemic administration approach for SIL-204, demonstrating ...

Revolution Medicines' promising KRAS inhibitors show potential in pancreatic cancer. See why we recommend a hold rating on ...

Quantum computing and artificial intelligence (AI) can be combined with classical computing methods to design and discover small-molecule candidates that target the cancer-driving KRAS protein, ...